tetano
Editor, Senior Moderator
Infect Dis Ther
. 2022 Apr 26.
doi: 10.1007/s40121-022-00638-4. Online ahead of print.
Patients with COVID-19 and HBV Coinfection are at Risk of Poor Prognosis
Shanshan Yang[SUP] #[/SUP][SUP] 1 2 [/SUP], Shengshu Wang[SUP] #[/SUP][SUP] 2 3 [/SUP], Mingmei Du[SUP] #[/SUP][SUP] 1 [/SUP], Miao Liu[SUP] 4 5 [/SUP], Yunxi Liu[SUP] 6 [/SUP], Yao He[SUP] 7 [/SUP]
Affiliations
Abstract
Introduction: This study aimed to determine whether there is a difference in the risk of death/critical illness between different stages of hepatitis B virus (HBV) (resolved hepatitis B, HBeAg (-) chronic hepatitis B [CHB]/infection, HBeAg (+) CHB/infection, and HBV reactivation) coinfected with coronavirus disease 2019 (COVID-19); and if there is a difference, whether it is due to abnormal liver function and to what extent.
Methods: This cohort study included all COVID-19 inpatients of a single-center tertiary care academic hospital in Wuhan, Hubei, China, between February 4, 2020, and follow-up to April 14, 2020. A total of 2899 patients with COVID-19 were included as participants in this study, and they were divided into five groups based on hepatitis B infection status. Follow-up was conducted for mortality and ICU admission during hospitalization.
Results: The median follow-up time was 39 days (IQR, 30-50), with 66 deaths and 126 ICU admissions. After adjustment, compared with patients without CHB, the hazard ratio (HR) for ICU admission was 1.86 (95% CI: 1.05-3.31) for patients with HBeAg (+) CHB/infection. The HR for death was 3.19 (95% CI: 1.62-6.25) for patients with HBeAg (+) CHB/infection. The results for the mediating effect indicated that the total effect of HBeAg (+) CHB/infection on death/ICU stay was partially mediated by abnormal liver function, which accounted for 79.60% and 73.53%, respectively.
Conclusion: Patients with COVID-19 coinfected with HBV at the HBeAg (+) CHB/infection stage have an increased risk of poor prognosis, and abnormal liver function partially mediates this increased risk of poor prognosis caused by the coinfection.
Keywords: COVID-19; Coinfection; Hepatitis B virus; Prognosis.
. 2022 Apr 26.
doi: 10.1007/s40121-022-00638-4. Online ahead of print.
Patients with COVID-19 and HBV Coinfection are at Risk of Poor Prognosis
Shanshan Yang[SUP] #[/SUP][SUP] 1 2 [/SUP], Shengshu Wang[SUP] #[/SUP][SUP] 2 3 [/SUP], Mingmei Du[SUP] #[/SUP][SUP] 1 [/SUP], Miao Liu[SUP] 4 5 [/SUP], Yunxi Liu[SUP] 6 [/SUP], Yao He[SUP] 7 [/SUP]
Affiliations
- PMID: 35471766
- DOI: 10.1007/s40121-022-00638-4
Abstract
Introduction: This study aimed to determine whether there is a difference in the risk of death/critical illness between different stages of hepatitis B virus (HBV) (resolved hepatitis B, HBeAg (-) chronic hepatitis B [CHB]/infection, HBeAg (+) CHB/infection, and HBV reactivation) coinfected with coronavirus disease 2019 (COVID-19); and if there is a difference, whether it is due to abnormal liver function and to what extent.
Methods: This cohort study included all COVID-19 inpatients of a single-center tertiary care academic hospital in Wuhan, Hubei, China, between February 4, 2020, and follow-up to April 14, 2020. A total of 2899 patients with COVID-19 were included as participants in this study, and they were divided into five groups based on hepatitis B infection status. Follow-up was conducted for mortality and ICU admission during hospitalization.
Results: The median follow-up time was 39 days (IQR, 30-50), with 66 deaths and 126 ICU admissions. After adjustment, compared with patients without CHB, the hazard ratio (HR) for ICU admission was 1.86 (95% CI: 1.05-3.31) for patients with HBeAg (+) CHB/infection. The HR for death was 3.19 (95% CI: 1.62-6.25) for patients with HBeAg (+) CHB/infection. The results for the mediating effect indicated that the total effect of HBeAg (+) CHB/infection on death/ICU stay was partially mediated by abnormal liver function, which accounted for 79.60% and 73.53%, respectively.
Conclusion: Patients with COVID-19 coinfected with HBV at the HBeAg (+) CHB/infection stage have an increased risk of poor prognosis, and abnormal liver function partially mediates this increased risk of poor prognosis caused by the coinfection.
Keywords: COVID-19; Coinfection; Hepatitis B virus; Prognosis.